[
    [
        {
            "time": "2021-08-30",
            "original_text": "东吴证券维持贝达药业买入评级，2021年中报点评：业绩符合我们的预期，凯美纳+贝美纳双驱动，持续巩固非小细胞肺癌领域优势",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "贝美纳",
                    "非小细胞肺癌",
                    "双驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券维持贝达药业买入评级，2021年中报点评：业绩符合我们的预期，凯美纳+贝美纳双驱动，持续巩固非小细胞肺癌领域优势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "华西证券维持贝达药业买入评级：业绩符合预期，新产品快速拓展市场",
            "features": {
                "keywords": [
                    "贝达药业",
                    "新产品",
                    "市场拓展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华西证券维持贝达药业买入评级：业绩符合预期，新产品快速拓展市场",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "贝达药业第四代EGFR抑制剂BPI-361175项目I期临床研究首例受试者入组",
            "features": {
                "keywords": [
                    "贝达药业",
                    "EGFR抑制剂",
                    "BPI-361175",
                    "临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业第四代EGFR抑制剂BPI-361175项目I期临床研究首例受试者入组",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "华鑫证券维持贝达药业推荐评级：业绩符合预期，研发稳步推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "研发",
                    "推进"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华鑫证券维持贝达药业推荐评级：业绩符合预期，研发稳步推进",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "天风证券维持贝达药业增持评级：业绩增长符合预期，肺癌领域多款药物取得进展",
            "features": {
                "keywords": [
                    "贝达药业",
                    "肺癌",
                    "药物进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券维持贝达药业增持评级：业绩增长符合预期，肺癌领域多款药物取得进展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "国盛证券维持贝达药业买入评级：上半年表现亮眼，收获颇丰，Q2实现高速增长",
            "features": {
                "keywords": [
                    "贝达药业",
                    "上半年",
                    "Q2",
                    "高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券维持贝达药业买入评级：上半年表现亮眼，收获颇丰，Q2实现高速增长",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "凯美纳持续放量 贝达药业上半年净利润超2亿",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "净利润",
                    "放量"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯美纳持续放量 贝达药业上半年净利润超2亿",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "贝达药业2021H1净利润同比增长近50%，凯美纳十年累计销售收入超100亿",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "净利润",
                    "同比增长"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业2021H1净利润同比增长近50%，凯美纳十年累计销售收入超100亿",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "中泰证券维持贝达药业买入评级：业绩符合预期，EGFR、ALK抑制剂双轮驱动主业强劲增长",
            "features": {
                "keywords": [
                    "贝达药业",
                    "EGFR",
                    "ALK",
                    "抑制剂",
                    "双轮驱动"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券维持贝达药业买入评级：业绩符合预期，EGFR、ALK抑制剂双轮驱动主业强劲增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "东莞证券维持贝达药业推荐评级，2021年中报点评：Q2业绩实现快增，研发持续推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "Q2",
                    "业绩快增",
                    "研发"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东莞证券维持贝达药业推荐评级，2021年中报点评：Q2业绩实现快增，研发持续推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "贝达药业：中期盈利2.15亿人民币，同比增长49.57%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "中期盈利",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：中期盈利2.15亿人民币，同比增长49.57%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]